One of TR 27’s most influential contributions is the for CCI. Integrity is not a single test – it must be assured at multiple stages:
Established foundational concepts for pharmaceutical package integrity.
, titled "Pharmaceutical Package Integrity," is a foundational consensus document published by the Parenteral Drug Association (PDA) in 1998. It provides comprehensive guidance on evaluating the barrier qualities and integrity of pharmaceutical packaging throughout a product's lifecycle. Overview and Purpose
Ensuring the test can detect leaks that could compromise product quality.
Modern regulatory bodies, including the FDA and EMA (via Annex 1 updates), strongly prefer deterministic, non-destructive test methods for routine production and stability testing over the older probabilistic methods described in the early sections of TR 27. Implementing TR 27 Guidelines in Industry pda technical report 27 pdf
Establishing baseline expectations for evaluating rigid, semi-rigid, and flexible packaging systems.
Your protocol’s “Acceptance Criteria” section should quote TR 27’s guidance on correlating leak size to microbial challenge. Example:
TR 27 shifted the industry mindset from end-product sterility testing to process-based assurance via validated, sensitive integrity test methods.
(A specific type of liquid tracer test, often called the "dye ingress" method) One of TR 27’s most influential contributions is
Offering strategies for integrity assessment during product development, manufacturing, and stability testing. Superseding Old Guidance: It replaced the earlier PDA Technical Information Bulletin No. 4 , reflecting advancements in sterile packaging complexity. Key Technical Areas Covered
Among the foundational documents guiding the pharmaceutical industry in this domain is the Parenteral Drug Association (PDA) Technical Report No. 27 (TR 27), titled Pharmaceutical Package Integrity . Published originally in 1998, TR 27 established the fundamental concepts of leak detection, risk assessment, and deterministic versus probabilistic testing methodologies.
Highly sensitive tracer gas method often utilized during the development and design phase to establish baseline package performance. 2. Probabilistic Leak Test Methods
Using the methodologies in TR 27 assists in identifying potential failure points in packaging design or manufacturing. It provides comprehensive guidance on evaluating the barrier
PDA Technical Report No. 27 (TR 27), "Pharmaceutical Package Integrity," is a 1998 guidance document that outlines strategies for assessing the container closure integrity (CCI) of pharmaceutical packaging. It emphasizes protecting sterile products by setting standards for microbial barriers, though it is being superseded by newer guidelines such as TR 86. The report is available for purchase on the PDA Bookstore . Technical Report No. 27: Pharmaceutical Package Integrity
TR 27 establishes a critical vocabulary:
The PDF of PDA TR 27 (available through PDA’s bookstore or technical libraries) should be required reading for every pharmaceutical engineer, quality assurance professional, and regulatory affairs specialist working with sterile products.
The technical report applies to all sterile pharmaceutical products, including: